Ben Bronstein - Aldeyra Director
| ALDX Stock | USD 4.20 0.26 6.60% |
Director
Dr. Ben Bronstein, M.D. is an Independent Director of Company.He has served as a member of Board of Directors since 2010, and from 2010 to 2011 served as Chief Executive Officer of Aldeyra Therapeutics, then known as Neuron Systems. Dr. Bronstein is Executive Vice President, Clinical Development at Aclaris Therapeutics, Inc. Previously he was an active advisor and consultant to life science companies. He is a boardcertified pathologist and dermatopathologist, with over 20 publications. Dr. Bronstein began his professional career on the staff of the Massachusetts General Hospital and on the faculty of Harvard Medical School. He has spent the past 28 years in entrepreneurial and management roles in life science companies and VC firms. Dr. Bronstein has founded or held senior management positions at several venturebacked life science firms, including BioSurface Technology, Inc., a regenerative medicine company Peptimmune, Inc., an immunotherapeutics company and Vidus Ocular, Inc., a Yale University spinout developing an implantable device for the treatment of glaucoma. Dr. Bronstein has served as Chief Medical Officer of Stealth BioTherapeutics, Inc., as a Visiting Scholar at the Wyss Institute of Biologically Inspired Engineering at Harvard Medical School and as a founder and Senior Vice President of Access BridgeGap Ventures, the life science investment unit of Access Industries, Inc. Dr. Bronstein serves on the boards of directors of several privately held life science . He is also a member of the Weill Cornell Medical College Faculty Industry Council and the Coulter Oversight Committee at Boston University since 2010.
| Age | 67 |
| Tenure | 14 years |
| Professional Marks | MBA |
| Address | 131 Hartwell Avenue, Lexington, MA, United States, 02421 |
| Phone | 781 761 4904 |
| Web | https://www.aldeyra.com |
Aldeyra Management Efficiency
The company has return on total asset (ROA) of (0.1623) % which means that it has lost $0.1623 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2773) %, meaning that it created substantial loss on money invested by shareholders. Aldeyra's management efficiency ratios could be used to measure how well Aldeyra manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.27 in 2024. Return On Capital Employed is likely to drop to -0.36 in 2024. At this time, Aldeyra's Non Current Assets Total are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 4.7 M in 2024, whereas Total Assets are likely to drop slightly above 78.6 M in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Jean Belanger | Acasti Pharma | N/A | |
| Adrian Montgomery | Acasti Pharma | N/A | |
| Gregory French | Pulmatrix | 53 | |
| Zhi Yang | Jaguar Animal Health | 61 | |
| Matthew Sherman | Pulmatrix | 61 | |
| Robertson Gilliland | Adial Pharmaceuticals | 37 | |
| Terrance McGuire | Pulmatrix | 61 | |
| Tony Goodman | Adial Pharmaceuticals | 60 | |
| Valier Boivin | Acasti Pharma | N/A | |
| Richard Conley | Pulmatrix | 63 | |
| Akihisa Akao | Pulmatrix | 59 | |
| John Micek | Jaguar Animal Health | 64 | |
| JeanDaniel Belanger | Acasti Pharma | N/A | |
| Kurt Graves | Pulmatrix | 47 | |
| Michael Higgins | Pulmatrix | 55 | |
| Pierre Fitzgibbon | Acasti Pharma | 60 | |
| Jiahao Qiu | Jaguar Animal Health | 31 | |
| Gregory Divis | Jaguar Animal Health | 50 | |
| Richard Schottenfeld | Acasti Pharma | N/A | |
| Jeffrey Johnson | Jaguar Animal Health | 45 | |
| Reed Tuckson | Acasti Pharma | 63 | |
Management Performance
| Return On Equity | -0.28 | ||||
| Return On Asset | -0.16 |
Aldeyra Leadership Team
Elected by the shareholders, the Aldeyra's board of directors comprises two types of representatives: Aldeyra inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aldeyra. The board's role is to monitor Aldeyra's management team and ensure that shareholders' interests are well served. Aldeyra's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aldeyra's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gary Phillips, Independent Director | ||
| David Clark, Chief Medical Officer | ||
| Stephen Tulipano, CFO, Principal Financial Officer, Principal Accounting Officer | ||
| David McMullin, Senior Vice President - Corporate Development and Strategy | ||
| Martin Joyce, Independent Director | ||
| Ben Bronstein, Director | ||
| Boyd Clarke, Chairman of the Board | ||
| Neal Walker, Independent Director | ||
| David Burke, Head Relations | ||
| Jesse Treu, Independent Director | ||
| Mary MPH, Sr. VP of Regulatory Affairs | ||
| Joshua Reed, CFO | ||
| Kelly Mizer, Vice Operations | ||
| Stephen Machatha, Senior Vice President - Technical Operations | ||
| Todd Brady, President CEO, Director | ||
| Scott Young, COO | ||
| David MD, Chief Medical Officer | ||
| Richard Douglas, Independent Director |
Aldeyra Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aldeyra a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.28 | ||||
| Return On Asset | -0.16 | ||||
| Current Valuation | 120.2 M | ||||
| Shares Outstanding | 59.41 M | ||||
| Shares Owned By Insiders | 1.99 % | ||||
| Shares Owned By Institutions | 61.57 % | ||||
| Number Of Shares Shorted | 2.36 M | ||||
| Price To Earning | (4.44) X | ||||
| Price To Book | 2.09 X | ||||
| EBITDA | (42.53 M) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Aldeyra in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Aldeyra's short interest history, or implied volatility extrapolated from Aldeyra options trading.
Pair Trading with Aldeyra
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aldeyra position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aldeyra will appreciate offsetting losses from the drop in the long position's value.Moving against Aldeyra Stock
| 0.69 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.69 | GILD | Gilead Sciences Sell-off Trend | PairCorr |
| 0.54 | GNLX | Genelux Common | PairCorr |
| 0.52 | PRFX | PainreformLtd | PairCorr |
| 0.51 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
The ability to find closely correlated positions to Aldeyra could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aldeyra when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aldeyra - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aldeyra to buy it.
The correlation of Aldeyra is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aldeyra moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aldeyra moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aldeyra can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aldeyra. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy Aldeyra Stock please use our How to Invest in Aldeyra guide.Note that the Aldeyra information on this page should be used as a complementary analysis to other Aldeyra's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Complementary Tools for Aldeyra Stock analysis
When running Aldeyra's price analysis, check to measure Aldeyra's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aldeyra is operating at the current time. Most of Aldeyra's value examination focuses on studying past and present price action to predict the probability of Aldeyra's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aldeyra's price. Additionally, you may evaluate how the addition of Aldeyra to your portfolios can decrease your overall portfolio volatility.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |
Is Aldeyra's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aldeyra. If investors know Aldeyra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aldeyra listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.64) | Return On Assets (0.16) | Return On Equity (0.28) |
The market value of Aldeyra is measured differently than its book value, which is the value of Aldeyra that is recorded on the company's balance sheet. Investors also form their own opinion of Aldeyra's value that differs from its market value or its book value, called intrinsic value, which is Aldeyra's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aldeyra's market value can be influenced by many factors that don't directly affect Aldeyra's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aldeyra's value and its price as these two are different measures arrived at by different means. Investors typically determine if Aldeyra is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aldeyra's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.